Neximmune Assets Non Current from 2010 to 2024

NEXI Stock  USD 5.51  0.18  3.16%   
Check Neximmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neximmune main balance sheet or income statement drivers, such as Net Interest Income of 1 M, Interest Income of 1 M or Depreciation And Amortization of 617.9 K, as well as many exotic indicators such as Price Earnings Ratio of 0.0108, Price To Sales Ratio of 0.0 or Dividend Yield of 0.0. Neximmune financial statements analysis is a perfect complement when working with Neximmune Valuation or Volatility modules.
  
This module can also supplement various Neximmune Technical models . Check out the analysis of Neximmune Correlation against competitors.
For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.

About Neximmune Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Neximmune income statement, its balance sheet, and the statement of cash flows. Neximmune investors use historical funamental indicators, such as Neximmune's Assets Non Current, to determine how well the company is positioned to perform in the future. Although Neximmune investors may use each financial statement separately, they are all related. The changes in Neximmune's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Neximmune's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Neximmune Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Neximmune. Please read more on our technical analysis and fundamental analysis pages.
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland. Neximmune operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 74 people.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Neximmune in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Neximmune's short interest history, or implied volatility extrapolated from Neximmune options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Neximmune offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Neximmune's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Neximmune Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Neximmune Stock:
Check out the analysis of Neximmune Correlation against competitors.
For more detail on how to invest in Neximmune Stock please use our How to Invest in Neximmune guide.
You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for Neximmune Stock analysis

When running Neximmune's price analysis, check to measure Neximmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neximmune is operating at the current time. Most of Neximmune's value examination focuses on studying past and present price action to predict the probability of Neximmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neximmune's price. Additionally, you may evaluate how the addition of Neximmune to your portfolios can decrease your overall portfolio volatility.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Stocks Directory
Find actively traded stocks across global markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Is Neximmune's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neximmune. If investors know Neximmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neximmune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(42.05)
Return On Assets
(0.78)
Return On Equity
(1.57)
The market value of Neximmune is measured differently than its book value, which is the value of Neximmune that is recorded on the company's balance sheet. Investors also form their own opinion of Neximmune's value that differs from its market value or its book value, called intrinsic value, which is Neximmune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neximmune's market value can be influenced by many factors that don't directly affect Neximmune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neximmune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neximmune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neximmune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.